Errant enzyme may cause AD plaque

Article

A faulty molecule may be responsible for the progression of mild cognitive impairment to Alzheimer’s disease, according to researchers from Mount Sinai School of Medicine in New York City.

A faulty molecule may be responsible for the progression of mild cognitive impairment to Alzheimer's disease, according to researchers from Mount Sinai School of Medicine in New York City.

A major effort is under way to find imaging biomarkers that will lead to earlier diagnosis of AD. One such promising marker is β-amyloid plaque, which is associated with AD. Researchers debate, however, whether the plaques cause AD or are a byproduct of the disease.

The Mount Sinai study, which appeared June 10 online in the journal Neurobiology of Aging, suggests the former.

People with AD exhibit elevated levels of β-amyloid peptides that cause plaque buildup in the brain. In the earliest stages of AD, the peptides proliferate, especially in the two connected brain regions critical for memory functions: the hippocampus and entorhinal cortex.

Dr. Giulio M. Pasinetti, director of the Neuroinflammation Research Center, and colleagues theorized that the early increase of β-amyloid peptides could be due to the shutoff in the brains of people at high-risk for developing AD of an insulin-degrading enzyme (IDE) that breaks down the peptides.

To assess possible changes in IDE during MCI, the investigators measured protein levels and enzymatic activity in postmortem brain tissue from 46 elderly subjects. They found that levels of β-amyloid peptides in the entorhinal cortex were inversely correlated with IDE activity in the hippocampus. These results support the idea that alterations in IDE might be causally related to β-amyloid peptide accumulation, starting in the earliest stages of AD, Pasinetti said.

If these results are confirmed, researchers suggest that boosting IDE activity pharmacologically may reverse β-amyloid peptide accumulation.

A loss of IDE activity had previously been shown to occur in severe AD dementia. The current results raise the possibility that a deficit in degradation of amyloid peptides from IDE could raise levels of toxic β-amyloid peptides even before AD dementia is diagnosed.

"We hope our research provides direction for preventive treatments to delay the onset of AD dementia by eliminating amyloid plaque-causing peptides in the brain," Pasinetti said.

For more information from the Diagnostic Imaging archives:

PET/CT imaging distinguishes potentially treatable dementias

Neuroimaging sharpens focus on mild cognitive impairment

Study taps cerebrospinal fluid to identify dementia

Study links Alzheimer's disease to abnormal cell division

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.